Targeted genome editing in hematopoietic stem and progenitor cells (HSPCs) using CRISPR/Cas9 can potentially provide a permanent cure for hematologic diseases. However, the utility of CRISPR/Cas9 systems for therapeutic genome editing can be compromised by their off-target effects. In this chapter, we outline the procedures for CRISPR/Cas9 off-target identification and validation in HSPCs. This method is broadly applicable to diverse CRISPR/Cas9 systems and cell types. Using this protocol, researchers can perform computational prediction and experimental identification of potential off-target sites followed by off-target activity quantification by next-generation sequencing.
Keywords: CRISPR/Cas9; GUIDE-seq; Genome editing; Hematopoietic stem and progenitor cells (HSPCs); Next-generation sequencing (NGS); Off-target.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.